European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma
暂无分享,去创建一个
V. Ambrosini | H. Sorbye | N. Fazio | A. Couvelard | U. Knigge | E. Grande | N. Reed | E. Tiensuu Janson | M. Tesselaar | Marianne Pavel | Emanuel Christ
[1] J. Furuse,et al. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System , 2022, JAMA oncology.
[2] H. Pommergaard,et al. Surgery in Patients with Gastro-Entero-Pancreatic Neuroendocrine Carcinomas, Neuroendocrine Tumors G3 and High Grade Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms , 2022, Current Treatment Options in Oncology.
[3] A. Couvelard,et al. An update on the development of concepts, diagnostic criteria, and challenging issues for neuroendocrine neoplasms across different digestive organs , 2022, Virchows Archiv.
[4] R. Berman,et al. Surgical Treatment of Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: An NCDB Analysis , 2022, Annals of Surgical Oncology.
[5] H. Sorbye,et al. Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas , 2022, The oncologist.
[6] D. Moore,et al. Expanding therapeutic opportunities for Extra-Pulmonary Neuroendocrine Carcinoma. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.
[7] M. Kanda,et al. Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System , 2021, Cancer discovery.
[8] A. Dasari,et al. Prognosis for Poorly Differentiated, High-Grade Rectal Neuroendocrine Carcinomas , 2021, Annals of Surgical Oncology.
[9] Xinchen Sun,et al. Clinicopathological analysis of 67 cases of esophageal neuroendocrine carcinoma and the effect of postoperative adjuvant therapy on prognosis , 2021, Medicine.
[10] S. Knappskog,et al. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms , 2021, Endocrine-related cancer.
[11] W. Weichert,et al. Neuroendocrine Differentiation in Conventional Colorectal Adenocarcinomas: Incidental Finding or Prognostic Biomarker? , 2021, Cancers.
[12] Zhi Peng,et al. Serum Biomarker Status with a Distinctive Pattern in Prognosis of Gastroenteropancreatic Neuroendocrine Carcinoma , 2021, Neuroendocrinology.
[13] M. Falconi,et al. A Multigenomic Liquid Biopsy Biomarker for Neuroendocrine Tumor Disease outperforms CgA and has Surgical and Clinical Utility. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] C. Luchini,et al. Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant? , 2021, Cancers.
[15] S. Mori,et al. Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma , 2021, Modern Pathology.
[16] Yibo Gao,et al. Multi-omics profiling of primary small cell carcinoma of the esophagus reveals RB1 disruption and additional molecular subtypes , 2021, Nature Communications.
[17] L. Shen,et al. Clinicopathological features and lymph node and distant metastasis patterns in patients with gastroenteropancreatic mixed neuroendocrine‐non‐neuroendocrine neoplasm , 2021, Cancer medicine.
[18] M. Ducreux,et al. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network. , 2021, European journal of cancer.
[19] Helen X. Chen,et al. A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609: High‐grade neuroendocrine neoplasm cohort , 2021, Cancer.
[20] N. Fazio,et al. Outcomes of small‐cell versus large‐cell gastroenteropancreatic neuroendocrine carcinomas: A population‐based study , 2021, Journal of neuroendocrinology.
[21] L. Thornblade,et al. Does surgery provide a survival advantage in non-disseminated poorly differentiated gastroenteropancreatic neuroendocrine neoplasms? , 2021, Surgery.
[22] M. Fassan,et al. Synaptophysin expression in V600EBRAF-mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. , 2021, European journal of cancer.
[23] W. Oyen,et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. , 2021, European journal of cancer.
[24] A. Cazes,et al. Biomarkers of Response to Etoposide-Platinum Chemotherapy in Patients with Grade 3 Neuroendocrine Neoplasms , 2021, Cancers.
[25] J. Strosberg,et al. Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms. , 2021 .
[26] H. Pommergaard,et al. Surgery of the primary tumour in 201 patients with high‐grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine‐non‐neuroendocrine neoplasms , 2021, Journal of neuroendocrinology.
[27] J. Strosberg,et al. Novel immunotherapy strategies for treatment of neuroendocrine neoplasms. , 2020, Translational gastroenterology and hepatology.
[28] Laura H. Tang,et al. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations , 2020, Neuroendocrinology.
[29] V. Miller,et al. Unique Genomic Landscape of High-Grade Neuroendocrine Cervical Carcinoma: Implications for Rethinking Current Treatment Paradigms , 2020, JCO precision oncology.
[30] C. Lindskog,et al. Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3 , 2020, Scientific Reports.
[31] D. Blazer,et al. Impact of Postoperative Chemotherapy on the Survival of Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinoma , 2020, Annals of Surgical Oncology.
[32] S. La Rosa,et al. Looking into digestive mixed neuroendocrine – nonneuroendocrine neoplasms: subtypes, prognosis, and predictive factors , 2020 .
[33] C. Zheng,et al. Adjuvant chemotherapy for patients with gastric neuroendocrine carcinomas or mixed adenoneuroendocrine carcinomas , 2020, The British journal of surgery.
[34] L. Xue,et al. Neoadjuvant chemotherapy improves the survival of patients with neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the stomach , 2020, Journal of Cancer Research and Clinical Oncology.
[35] L. Shen,et al. Etoposide and cisplatin versus irinotecan and cisplatin as the first‐line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study , 2020, Cancer.
[36] A. Lamarca,et al. Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis , 2020, Therapeutic advances in medical oncology.
[37] S. Mukhopadhyay,et al. INSM1 Is a Highly Specific Marker of Neuroendocrine Differentiation in Primary Neoplasms of the Gastrointestinal Tract, Appendix, and Pancreas. , 2020, American journal of clinical pathology.
[38] L. Shen,et al. Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial , 2020, Clinical Cancer Research.
[39] J. Itami,et al. Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy , 2019, Cancer medicine.
[40] M. Falconi,et al. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms? , 2019, Annals of Surgical Oncology.
[41] M. Esteller,et al. Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas , 2019, Clinical Cancer Research.
[42] Mohid S. Khan,et al. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres , 2019, World journal of gastroenterology.
[43] G. Pruneri,et al. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin , 2019, Neuroendocrinology.
[44] Kan Li,et al. Adjuvant Chemotherapy Versus Observation Following Resection for Patients With Nonmetastatic Poorly Differentiated Colorectal Neuroendocrine Carcinomas , 2019, Annals of surgery.
[45] A. Lièvre,et al. Chemotherapy in Resected Neuroendocrine Carcinomas of the Digestive Tract: A National Study from the French Group of Endocrine Tumours , 2019, Neuroendocrinology.
[46] H. Sorbye,et al. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. , 2019, Endocrine-related cancer.
[47] G. Nash,et al. Survival in Patients with High-Grade Colorectal Neuroendocrine Carcinomas: The Role of Surgery and Chemotherapy , 2019, Annals of Surgical Oncology.
[48] F. Spada,et al. Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas , 2019, Neuroendocrinology.
[49] L. Dizdar,et al. BRAFV600E mutation: A promising target in colorectal neuroendocrine carcinoma , 2018, International journal of cancer.
[50] M. Behera,et al. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. , 2019, The oncologist.
[51] R. Baum,et al. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients , 2018, The Journal of Nuclear Medicine.
[52] A. Vanoli,et al. Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis. , 2018, Endocrine-related cancer.
[53] H. Sorbye,et al. Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3) , 2018, Medical Oncology.
[54] H. Sorbye,et al. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases , 2018, Cancer.
[55] R. Hicks,et al. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[56] Yin Li,et al. Treatment Strategies and Prognostic Factors of Limited‐Stage Primary Small Cell Carcinoma of the Esophagus , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[57] H. Sorbye,et al. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[58] A. Bezjak,et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial , 2017, The Lancet. Oncology.
[59] Eva Ardanaz,et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. , 2017, The Lancet. Oncology.
[60] E. Baudin,et al. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort. , 2017, European journal of cancer.
[61] K. Matsuo,et al. Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study , 2017, Clinical Cancer Research.
[62] T. Meyer,et al. Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas , 2017, Journal of the National Cancer Institute.
[63] V. Hervieu,et al. Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers , 2017, Scientific Reports.
[64] M. Kloor,et al. Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas , 2017, Modern Pathology.
[65] A. Rashid,et al. Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal , 2017, American journal of clinical oncology.
[66] Long-Qi Chen,et al. Neuroendocrine carcinoma of the esophagus: clinical characteristics and prognostic evaluation of 49 cases with surgical resection. , 2016, Journal of Thoracic Disease.
[67] P. Stephens,et al. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. , 2016, Cancer discovery.
[68] A. Vanoli,et al. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories , 2016, Neuroendocrinology.
[69] M. A. O. Ignacio,et al. How to cite this article , 2016 .
[70] P. Rougier,et al. Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma , 2015, Medicine.
[71] C. Chougnet,et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. , 2015, Endocrine-related cancer.
[72] C. Leichman,et al. Radiation therapy improves survival in rectal small cell cancer - Analysis of Surveillance Epidemiology and End Results (SEER) data , 2015, Radiation oncology.
[73] M. Salhab,et al. Survival of Patients With Neuroendocrine Carcinoma of the Colon and Rectum: A Population-Based Analysis , 2015, Diseases of the colon and rectum.
[74] J. Furuse,et al. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system , 2014, Cancer science.
[75] M. V. van Velthuysen,et al. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. , 2013, European journal of cancer.
[76] Nicholas G Zaorsky,et al. Radiotherapy and chemotherapy are associated with improved outcomes over surgery and chemotherapy in the management of limited-stage small cell esophageal carcinoma. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[77] H. Sorbye,et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[78] H. Ueno,et al. Comparison of Chemotherapeutic Treatment Outcomes of Advanced Extrapulmonary Neuroendocrine Carcinomas and Advanced Small-Cell Lung Carcinoma , 2012, Neuroendocrinology.
[79] D. Ball,et al. Should extrapulmonary small cell cancer be managed like small cell lung cancer? , 2010, Cancer.
[80] G. Guyatt,et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.